Michigan Democrats introduced sweeping legislation Thursday that would cap insulin prices at $35 per month for all state residents, following similar federal measures that have failed to extend relief to patients across the country.
State Representatives Samantha Stevens and Marcus Johnson unveiled House Bill 4821 during a press conference at the Michigan State Capitol, arguing the measure would protect thousands of diabetic Michiganders from rising medication costs. The bill applies to all insulin formulations and delivery methods, regardless of insurance coverage or employment status.
“Insulin is not a luxury,” Stevens said, standing next to a Detroit resident who described rationing her insulin supply. “It’s a life-sustaining medication, and no Michigander should have to choose between their health and their rent.”
The legislation arrives as insulin prices continue climbing nationally, even after the federal government capped out-of-pocket costs at $35 monthly for Medicare beneficiaries in 2023. That federal provision excluded the roughly 1.2 million Michigan residents who rely on commercial insurance or who remain uninsured.
Closing Coverage Gaps
HB 4821 targets what advocates call a critical gap in existing protections. The federal cap applies only to seniors on Medicare and excludes insulin purchased through employer-sponsored health plans, Medicaid programs, or those without insurance altogether.
Data from the Michigan Health & Hospital Association indicates that insulin prices have more than tripled since 2000. Vials that cost $20 in 2000 now average between $70 and $80 on the commercial market. Patients using insulin pumps or multiple daily injections can spend upward of $300 monthly out of pocket.
Dr. Patricia Chen, an endocrinologist at the University of Michigan, testified before the House Health Policy Committee that many patients skip doses to extend supplies. “We’re seeing preventable complications from diabetes that directly trace back to cost-related rationing,” Chen said.
How the Bill Works
The legislation requires pharmaceutical manufacturers, pharmacy benefit managers, and health insurers to ensure insulin costs never exceed $35 monthly regardless of the dosage or formulation. The measure includes provisions for copays, deductibles, and coinsurance.
Unlike some previous proposals, HB 4821 does not impose price controls on manufacturers. Instead, it creates a rebate system where manufacturers and intermediaries must contribute to a state fund if insulin costs exceed the $35 threshold. The mechanism mirrors successful models implemented in other states.
Johnson, who represents a Detroit-area district, noted that the bill protects patients while maintaining market incentives. “We’re not trying to tell pharmaceutical companies what to charge,” Johnson said. “We’re setting a floor for consumers and letting the market adjust.”
The proposal faces support from patient advocacy groups but anticipated opposition from industry groups. The Pharmaceutical Research and Manufacturers of America did not immediately respond to requests for comment.
Economic Impact Questions
Healthcare economists remain divided on the long-term effects. Some argue that price caps reduce innovation incentives, while others counter that existing insulin formulations generate sufficient profits to offset reduced prices.
A fiscal analysis prepared by the House Fiscal Agency estimated the cap would cost the state between $12 million and $18 million annually in rebate fund administration. The analysis assumes insurers would pass savings to consumers rather than retaining them as profits.
State Senator Andrea Williams, a Democrat who plans to introduce a companion bill in the Senate, acknowledged concerns about unintended consequences. “We’re committed to monitoring implementation closely,” Williams said. “If manufacturers legitimately cannot maintain production at these prices, we’ll work with them on solutions.”
Timeline and Opposition
The bill is expected to advance to the full House Health Policy Committee in April. Party leaders indicated they hope to vote on the measure before the legislative session ends in July.
Republican House members voiced concerns about federal-state coordination. “Michigan shouldn’t duplicate federal efforts,” said Rep. David Martinez, ranking minority member on the health committee. “We should push Washington to extend protections to all Americans rather than creating patchwork state solutions.”
Healthcare industry groups warned the measure could disrupt existing insurance arrangements. The Michigan Health Insurance Association noted that manufacturers might respond by raising prices on other medications or reducing investment in Michigan manufacturing facilities.
Patient Perspective
At Thursday’s press conference, Maria Santos, a 41-year-old Type 1 diabetic from Grand Rapids, described managing her disease on a limited budget. “I’ve been using the same vial longer than recommended because I can’t afford replacements,” Santos said. “A cap like this could mean I finally take my medication as prescribed instead of as I can afford.”
Santos works full-time at a retail company offering health insurance. Her plan requires a $45 monthly copay for insulin, plus she pays deductibles before coverage kicks in. She estimated annual out-of-pocket costs at approximately $800.
The bill has attracted support from the Michigan Diabetes Council and patient groups across the state. A coalition of 15 disease advocacy organizations issued a joint statement supporting passage.
If approved, Michigan would join six other states that have enacted insulin price caps. Vermont, Delaware, New Mexico, and three others have implemented similar measures since 2022.
